These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 19853058)
1. Nonclinical development of biopharmaceuticals. Baumann A Drug Discov Today; 2009 Dec; 14(23-24):1112-22. PubMed ID: 19853058 [TBL] [Abstract][Full Text] [Related]
2. Preclinical development of therapeutic biologics. Baumann A Expert Opin Drug Discov; 2008 Mar; 3(3):289-97. PubMed ID: 23480264 [TBL] [Abstract][Full Text] [Related]
3. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells. Lebrec H; Narayanan P; Nims R J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250 [TBL] [Abstract][Full Text] [Related]
5. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products. Lewis RM; Cavagnaro J Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910 [TBL] [Abstract][Full Text] [Related]
6. Nonclinical safety evaluation of biotechnologically derived pharmaceuticals. Dempster AM Biotechnol Annu Rev; 2000; 5():221-58. PubMed ID: 10875002 [TBL] [Abstract][Full Text] [Related]
7. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective. Buckley LA; Dorato MA Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212 [TBL] [Abstract][Full Text] [Related]
8. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Serabian MA; Pilaro AM Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669 [TBL] [Abstract][Full Text] [Related]
9. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138 [TBL] [Abstract][Full Text] [Related]
10. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Kramer JA; Sagartz JE; Morris DL Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090 [TBL] [Abstract][Full Text] [Related]
11. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008 [TBL] [Abstract][Full Text] [Related]
12. Serum chemical biomarkers of cardiac injury for nonclinical safety testing. Walker DB Toxicol Pathol; 2006; 34(1):94-104. PubMed ID: 16507550 [TBL] [Abstract][Full Text] [Related]
13. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop. Buckley LA; Benson K; Davis-Bruno K; Dempster M; Finch GL; Harlow P; Haggerty HG; Hart T; Kinter L; Leighton JK; McNulty J; Roskos L; Saber H; Stauber A; Tabrizi M Int J Toxicol; 2008; 27(4):303-12. PubMed ID: 18821393 [TBL] [Abstract][Full Text] [Related]
14. Metabolites in safety testing. Robison TW; Jacobs A Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045 [TBL] [Abstract][Full Text] [Related]
15. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Martin PL; Breslin W; Rocca M; Wright D; Cavagnaro J Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):176-203. PubMed ID: 19462404 [TBL] [Abstract][Full Text] [Related]
16. Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate? Clarke J; Hurst C; Martin P; Vahle J; Ponce R; Mounho B; Heidel S; Andrews L; Reynolds T; Cavagnaro J Regul Toxicol Pharmacol; 2008 Feb; 50(1):2-22. PubMed ID: 17998153 [TBL] [Abstract][Full Text] [Related]
17. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials. EFSA GMO Panel Working Group on Animal Feeding Trials Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408 [TBL] [Abstract][Full Text] [Related]